Table of content
Medicamen Organics Introduction
Medicamen Organics Limited, incorporated in 1995, is a dynamic player in the pharmaceutical industry. With a commitment to quality and innovation, they develop, manufacture, and distribute a diverse range of pharmaceutical dosages. Their product portfolio includes generic tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders.
Brief about Company
Summary of the business of Medicamen Organics
Company is engaged in developing, manufacturing and distribution of broad range of pharmaceutical dosage including generic dosage in form of Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders for government (including both state and central governments) and private institutions as contract manufacturer / third party manufacturer. Market product to private pharma companies in domestic as well as international markets through third party distributors or on loan license basis. Further, our Company is also strategically focusing on establishing a direct presence in international market for an instance in fiscal 2023, we have directly exported our product in Burundi. We have a track record of operating B2B model which covers contract manufacturing model. Products are marketed across India as well as African, Commonwealth of Independent States (CIS) region and south East Asian Countries like Congo, Benin, Cameg, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan and Kenya by our third-party distributor.
History of Medicamen Organics
Company was incorporated on March 15, 1995 as ‘Panchdeep Pharmaceuticals Limited’, National Capital Territory (NCT) of Delhi and Haryana.
The Pioneer, Promoter and Managing Director of company, Mr. Bal Kishan Gupta, Whole Time Director Mr. Ashutosh Gupta and executive director Mr. Shailesh Guar have played a pivotal role for our Company’s growth and success. Promoter and directors have a combined experience of decades in the pharmaceutical products. Driven by the passion for building an integrated pharmaceutical company, backed by best quality and impeccable documentation, Promoter has been the pillar of our Company’s growth and has built a strong value system for Company. With his enriching experience and progressive thinking, we aim to continue to grow in the pharmaceutical industry.
company has two manufacturing units located as follows:
- Unit-1- 60, Sector 6A, I.I.E. Sidcul, Ranipur, Haridwar-249403, India
- Unit-2- 61, Sector 6A, I.I.E. Sidcul, Ranipur, Haridwar-249403, India
Promoters and Board of directors of Medicamen Organics
The Promoter of our Company is Bal Kishan Gupta
Board of directors of Medicamen Organics
| Name | Designation |
| Bal Kishan Gupta | Chairman and Managing Director |
| Ashutosh Gupta | Whole-time Director |
| Shailesh Harimohan Gaur | Executive Director |
| Rakesh Kumar | Independent Director |
| Rajinder Kumar Gupta | Independent Director |
| Sachin Gupta | Independent Director |
| Ms. Sneh Gaur | Non-Executive Non-Independent Director |
Share Holding pattern of Medicamen Organics
| S.No. | Particulars | As a % of Pre- Issue Capital |
| Promoters | ||
| 1. | Mr. Bal Kishan Gupta | 70.96 |
| Total (A) | 70.96 | |
| Promoter Group | ||
| 2. | Mr. Ashutosh Gupta | 6.83 |
| 3. | M/s B. K. Gupta & Sons | 0.03 |
| 4. | Ms. Ritu Gupta | 3.33 |
| 5. | Mr. Ishaan Gupta | 0.08 |
| Total (B) | 10.25 | |
| 6 | Public | 18.79 |
Qualitative Factors of Medicamen Organics
- Experienced Promoters and Management Team;
- Long standing relationships with customers;
- Efficient operational team;
- Consistent financial performance;
Strategy
- 1.Improve global presence
- 2.Maintaining edge over competitors
- 3.Expansion Plan
- 4.Customer Satisfaction
Industry Outlook
Indian Pharmaceutical Industry
According to a recent EY FICCI report, there has been growing consensus over providing new innovative therapies to patients, Indian pharmaceutical market is estimated to touch US$ 130 billion in value by the end of 2030. Meanwhile, the global market size of pharmaceutical products is estimated to cross over the US$ 1 trillion mark in 2024.
India is the largest provider of generic drugs globally and is known for its affordable vaccines and generic medications. The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volume after evolving into a thriving industry growing at a CAGR of 9.43% in the past nine years. Generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics are some of the major segments of the Indian pharma industry. India has the most pharmaceutical manufacturing facilities that comply with the US Food and Drug Administration (USFDA) and has 500 API producers that makeup around 8% of the worldwide API market.
Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US, and 25% of all medicine in the UK. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers with the potential to steer industry ahead to greater heights. Presently, over 80% of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) are supplied by Indian pharmaceutical firms. India is rightfully known as the “pharmacy of the world” due to the low cost and high quality of its medicines.
Indian pharmaceutical industry is known for its generic medicines and low-cost vaccines globally. Transformed over the years as a vibrant sector, presently Indian Pharma ranks third in pharmaceutical production by volume. The Pharmaceutical industry in India is the third largest in the world in terms of volume and 14th largest in terms of value. The Pharma sector currently contributes to around 1.72% of the country’s GDP.
Indian Pharmaceutical Market Size
The market size of India’s pharmaceuticals industry is expected to reach US$ 65 billion by 2024, and ~US$ 130 billion by 2030. According to government data, the Indian pharmaceutical industry is worth approximately US$ 50 billion with over US$ 25 billion of the value coming from exports. About 20% of the global exports in generic drugs are met by India. India is among the top 12 destinations for biotechnology worldwide and 3rd largest destination for biotechnology in the Asia Pacific. In 2022, India’s Biotechnology industry crossed US$ 80.12 billion, growing 14% from the previous year.
During FY18 to FY23, the Indian pharmaceutical industry logged a compound annual growth rate (CAGR) of 6-8%, primarily driven by an 8% increase in exports and a 6% rise in the domestic market. The domestic pharmaceutical industry would likely reach US$ 57 billion by FY25 and see an increase in operating margins of 100-150 basis points (bps). The Indian pharmaceutical industry has seen a massive expansion over the last few years and is expected to reach about 13% of the size of the global pharma market while enhancing its quality, affordability, and innovation.
The biosimilar market in India is estimated to grow at a compounded annual growth rate (CAGR) of 22% to become US$ 12 billion by 2025. This would represent almost 20% of the total pharmaceutical market in India. India is the 3rd largest producer of API accounting for an 8% share of the Global API Industry. About 500+ different APIs are manufactured in India, and it contributes 57% of APIs to the prequalified list of the WHO. India is the 3rd largest producer of API accounting for an 8% share of the Global API Industry. About 500+ different APIs are manufactured in India, and it contributes 57% of APIs to the prequalified list of the WHO.
Indian pharma companies have a substantial share in the prescription market in the US and EU. The largest number of FDA- approved plants outside the US is in India. According to the Indian Economic Survey 2021, the domestic market is expected to grow 3x in the next decade. India’s domestic pharmaceutical market stood at US$ 42 billion in 2021 and is likely to reach US$ 65 billion by 2024 and further expand to reach US$ 120-130 billion by 2030. India’s biotechnology industry comprises biopharmaceuticals, bio-services, bio-agriculture, bio-industry, and bioinformatics. The Indian biotechnology industry was valued at US$ 70.2 billion in 2020 and is expected to reach US$ 150 billion by 2025. India’s medical devices market stood at US$ 10.36 billion in FY20. The market is expected to increase at a CAGR of 37% from 2020 to 2025 to reach US$ 50 billion. As of August 2021, CARE Ratings expect India’s pharmaceutical business to develop at an annual rate of ~11% over the next two years to reach more than US$ 60 billion in value.
In the global pharmaceuticals sector, India is a significant and rising player. India is the world’s largest supplier of generic medications, accounting for 20% of the worldwide supply by volume and supplying about 60% of the global vaccination demand. The Indian pharmaceutical sector is worth US$ 42 billion worldwide. In August 2021, the Indian pharmaceutical market increased by 17.7% annually, up from 13.7% in July 2020.
Pharmaceutical Exports to continue witnessing growth
Pharmaceuticals is one of the top ten attractive sectors for foreign investment in India. The pharmaceutical exports from India reach more than 200 nations around the world, including highly regulated markets of the USA, West Europe, Japan, and Australia. India supplied around 45 tonnes and 400 million tablets of hydroxychloroquine to around 114 countries globally.
India’s drugs and pharmaceutical exports stood at Rs. 2,08,231 crore (US$ 25.3 billion) for FY23, as per the data by Pharmexcil. India’s exports of Drugs and pharmaceuticals stood at US$ 6.59 billion during April-June 2023. Exports of Drugs and pharmaceuticals were estimated to be at US$ 2.48 billion in March 2023 and shared 6.47% of the total exports of the month.
R & D spending in Indian pharmaceuticals
The biotechnology and pharmaceutical sectors have showcased resilience and grit in the face of the pandemic, continuously evolving and innovating for better outcomes. The industry has witnessed innovation in the fields of new vaccine technology and treatment methods as well as in the R&D that goes behind making these vaccines and treatments. Utilizing modern technologies to manufacture pharmaceuticals, improve scientific procedures, and identify novel treatment approaches is fast catching on.
Trends in the Indian Pharmaceuticals Sector
Up to 100%, FDI has been allowed through automatic routes for Greenfield pharmaceuticals projects. For Brownfield Pharmaceuticals projects, FDI allowed is up to 74% through automatic route and beyond that through government approval. The FDI inflows in the Indian drugs and pharmaceuticals sector reached US$ 21.46 billion between April 2000 and March 2023. This constitutes almost 3.38% of the total FDI inflow received across sectors.
In August 2023, Union Minister for Labour & Employment and Environment, Forest and Climate Change Mr. Bhupender Yadav launched Chemotherapy Services in 30 ESIC Hospitals across the country. An MoU was signed on June 4, 2023, between the Indian Pharmacopoeia Commission (IPC), Ministry of Health & Family Welfare, Government of India, and Ministry of Health, Government of Suriname for Recognition of Indian Pharmacopoeia (IP) in Suriname. In May 2023, the Ministry of Minority Affairs and the Ministry of Ayush joined hands to advance the Unani System of Medicine in India.
Prime Minister Mr. Narendra Modi during his Independence Day 2023 speech said that the government has plans to increase the number of ‘Jan Aushadhi Kendras’ from 10,000 to 25,000. The Department of Pharmaceuticals will soon launch the Scheme for the Promotion of Research and Innovation in Pharma (PRIP) MedTech Sector. The scheme has been approved by the Union Cabinet for a period of five years starting from 2023-24 to 2027-28 with a total outlay of Rs. 5,000 crore (US$
604.5 million). Emcure Pharmaceuticals Limited (EPL) became the first-ever company to launch Orofer FCM 750, a new extension of its parenteral iron brand containing Ferric carboxymaltose (FCM). The dose is suitable for most Indian patients with iron deficiency and iron deficiency anemia.
Road Ahead for Indian Pharmaceutical Sector
The pharmaceutical industry in India is a significant part of the nation’s foreign trade and offers lucrative potential for investors. Millions of people around the world receive affordable and inexpensive generic medications from India, which also runs a sizable number of plants that adhere to Good Manufacturing Practices (GMP) standards set by the World Health Organization (WHO) and the United States Food and Drug Administration (USFDA).
Among nations that produce pharmaceuticals, India has long held the top spot. Medicine spending in India is projected to grow 9-12% over the next five years, leading India to become one of the top 10 countries in terms of medicine spending. Going forward, better growth in domestic sales would also depend on the ability of companies to align their product portfolio towards chronic therapies for diseases such as cardiovascular, anti-diabetes, anti-depressants, and anti-cancers, which are on the rise.
Business Data of Medicamen Organics
Business Model of Medicamen Organics
- Contract Manufacturing:
- Primary business model is B2B contract manufacturing models where we partner with pharmaceutical companies who are third-party providers who market and sell the products to various companies engaged in ethical marketing as well as generics in International Market and Domestic Markets and has strong and independent sales and distribution networks for the marketing of our products. As of December 31, 2023, we along with our partners a total of 84 products registration under the name of the partners. Under this model, we own the development rights and marketing rights are owned by the partner. This model is adopted for our products across key markets including India.
- As on September 30, 2023 we have entered into contract manufacturing with 38 domestic partners and 12 merchant exporters.
- Government Contract
- participate in government tenders for supply of our product as per their requirement to government hospitals, government departments, Government PSU, Government armed forces etc. (“Government Contracts”). The advantages of government business include bulk quantity, committed volume, and advantages in purchase price due to high volume. As on September 30, 2023 we have served 11 government institution.
Verticals of Medicamen Organics
Products offerings can be classified in following major categories:
- Capsules: Various capsule formulation/compositions are being manufactured by us including but not limited to the following:
- Rabeprazole and Domperidone to treat with Hyperacidity.
- Tacrolimus Capsule belongs to a class of drugs known as immunosuppressants.
- Ribavirin capsules is an antiviral medicine that is used in the treatment of chronic hepatitis C virus (HCV) infection. It prevents the multiplication of virus in human cells and clears up the infection.
- Ointment/External Preparation: are producing antifungal/anti-bacterial formulations like Miconazole, Nystatin, Clotrimazole, Nadifloxacin, Mometasone in single as well as a composition form like cream and Gel. Topical Diclofenac, Salicylic acid composition are also being manufactured.
- Suspension: A variety of cough syrups, Multivitamin/Minerals, Calcium supplements, Antacid liquids, Iron supplements, Laxative liquids, Anthelmetic suspensions, anti-pyritic and anti-inflammatory suspensions are our key products.
- Dry Powder Sachet: are manufacturing sachets like pre and probiotic in granular form. Diclofenac Potassium and Sodium granules for oral administration.
- Tablet: (also known as a pill): are producing various composition of Ferrous and Folic Acid tablets. These tablets are widely used as an iron supplement to treat or prevent low blood levels of iron (such as those caused by anemia or pregnancy). Iron being an important mineral that the body needs to produce red blood cells keeps, an individual in good health. The formulation is developed in a manner to fulfil the deficiency quickly.
Product category wise revenue bifurcation of Medicamen Organics
The revenue bifurcation of the company for last three years as per restated standalone financial Statement are as follows:
(₹ in Lakhs)
| Particulars | Sept 30, 2023 | For the year ended March 31 | ||||||
| 2023 | 2022 | 2021 | ||||||
| Sales | % | Sales | % | Sales | % | Sales | % | |
| Capsules | 16.64 | 1.47 | 498.39 | 22.50 | 87.64 | 4.18 | 455.48 | 18.19 |
| Ointment | 4.02 | 0.36 | 297.60 | 13.44 | 364.62 | 17.38 | 133.41 | 5.33 |
| Suspension | 242.65 | 21.43 | 14.32 | 0.65 | 53.05 | 2.53 | 12.92 | 0.52 |
| Dry Powder Sachet | 32.60 | 2.88 | 155.08 | 7.00 | 33.48 | 1.60 | 2.50 | 0.10 |
| Tablet | 733.57 | 64.80 | 1106.91 | 49.98 | 1504.81 | 71.74 | 1879.74 | 75.06 |
| Other operating Revenues | 102.51 | 9.06 | 142.41 | 6.43 | 53.93 | 2.57 | 20.27 | 0.81 |
| Total Sales | 1132.00 | 100.00 | 2214.71 | 100.00 | 2097.52 | 100.00 | 2504.33 | 100.00 |
Channel wise breakup of Medicamen Organics
(₹ in lakhs)
| S.No. | Customers | Sept 30, 2023 | Fiscal 2023 | Fiscal 2022 | Fiscal 2021 | ||||
| Revenue earned (₹ in lakhs) | % of total revenue | Revenue earned (₹ in lakhs) | % of total revenue | Revenue earned (₹ in lakhs) | % of total revenue | Revenue earned (₹ in lakhs) | % of total revenue | ||
| 1. | Government Contract | 15.94 | 1.41 | 361.13 | 16.31 | 71.75 | 3.42 | 333.92 | 13.33 |
| 2. | Contract Manufacturing | 1116.05 | 98.59 | 1853.59 | 83.69 | 2025.77 | 96.58 | 2170.41 | 86.67 |
| Total | 1132.00 | 100.00 | 2214.71 | 100.00 | 2097.52 | 100.00 | 2504.33 | 100.00 | |
Machinery/Plants/Factory of Medicamen Organics
Company have 2 (two) manufacturing facilities in Haridwar. We have all required machinery and equipment inhouse to manufacture according to current order flow and we have ample spare capacities to fulfil more orders and facilitate growth. We also have self-sufficient inhouse Quality control laboratory separately for each facility to facilitate all testing requirements for both the manufacturing facilities. We manufacture quality pharmaceutical products in controlled environment and also maintain an inhouse engineering department to cater to preventive maintenance and wear and tear needs.
Capacity Utilization of Medicamen Organics
Unit I
| Year | FY 2023-2024(April-Sept 2023) | FY 2022-2023 | FY 2021-2022 | FY 2020-2021 |
| Installed Capacity(in Lakh tablets) | 5400 | 10800 | 10800 | 10800 |
| Utilized Capacity(in Lakh tablets) | 5292 | 9720 | 9288 | 8964 |
| % Capacity Utilization | 98% | 90% | 86% | 83% |
Unit II
| FY – 2023 – 2024 (Period April to September) | |||
| Product Offerings | Installed Capacity | Utilized capacity | % of Utilization |
| Tablets(in Lakh tablets) | 5400 | 3888 | 72 |
| Suspension (in Litre) | 468000 | 299520 | 64 |
| Capsules(in Lakh Capsule) | 390 | 156 | 40 |
| Ointment (in Kg) | 46800 | 17784 | 38 |
| Dry Powder Sachets(in Number) | 1872000 | 823680 | 44 |
Valuable partners of Medicamen Organics
- Ajanta pharma ltd
- Anglo-French Drugs & Industrial ltd
- Bestochem
- Dr.Morepen
- Emami Frank Ross
- Europa Biocare Pvt.Ltd
- Genmart
- GrVety Lifecare LLp
- Healing Pharma
- Jagsonpal
- John Lee
- Kilitch Drugs
- Knoll
- Livealth Bio pharma Pvt. ltd
Peer company comparison with Medicamen Organics
| Name of the Company | Face Value (₹) | Current Market Price | EPS (₹) | P/E Ratio | RoNW (%) | Net Asset Value Per Share | Total Income (₹ in Lakhs) | |
| Basic | Diluted | |||||||
| Medicamen Organics Limited | 10.00 | 34 | 1.60 | 1.60 | 24.3 | 11.25 | 14.20 | 2,296.24 |
| Peer Group | ||||||||
| Brooks Laboratories Ltd | 10.00 | 133.25 | (12.57) | (12.57) | 10.60 | -28.26 | 30.10 | 6,340.80 |
| Cian Healthcare Ltd | 10.00 | 23.15 | 0.43 | 0.43 | 53.84 | 1.75 | 22.40 | 6,809.94 |
| Zenotech Laboratories Ltd | 10.00 | 73.64 | 1.90 | 1.90 | 38.76 | 14.08 | 14.20 | 4350.80 |
Group companies of Medicamen Organics
- Redline Health Care Private Limited
Business risk factors of Medicamen Organics
- The Company is dependent on few numbers of customers for sales. Loss of any of this large customer may affect revenues and profitability
- Top ten customers contribute 68.67%, 62.00%, 66.45% and 55.82% of our total sales for the six months ended September 30, 2023 and financial year ended on March 31, 2023, 2022 and 2021, respectively
- The Company is dependent on few suppliers for purchase of product. Loss of any of these large suppliers may affect business operations.
- Top ten suppliers contribute 47.48%, 61.25%, 38.71% and 32.10% of our total purchase for the six months ended September 30, 2023 and financial year ended on March 31, 2023, 2022 and 2021.
- Group Company, Redline Health Care Private Limited may have conflict of interest with us as it is engaged in similar business and may compete with us.
- Company has experienced negative cash flow in the past and may continue to do so in the future, which could have a material adverse effect on our business, prospects, financial condition, cash flows and results of operations
(₹ in lakhs)
| Particulars | Six-month period ended Sept 30, 2023 | March 31,2023 | March 31,2022 | March 31,2021 |
| Net Cash Flow from/ (used in) Operating Activities | (48.76) | (58.37) | 3.74 | (116.42) |
| Net cash generated from/ (used in) investing activities | (6.51) | (28.13) | (59.31) | (1.56) |
| Net Cash Flow from/ (used in) Financing Activities | 51.65 | 93.69 | 18.28 | 126.98 |
Competition
compete with organized and as well as unorganized players in the industry with better financial position, market share, product ranges, human and other resources. Manufacturing Capacities, Branding and marketing are the key factors in the industry where larger players are in a better position to market their products. Company have continued competing vigorously to capture more market share and manage our growth in an optimal way. To that effect, we have been launching newer products across different grades and quality in the market to cater and penetrate in new geographical region.
Financials of Medicamen Organics
Key Financial Ratios
| Ratios | For the year ended March 31, 2022 | For the year ended March 31, 2021 | Variation |
| Current Ratio | 0.88 | 0.86 | 1.16% |
| Debt-Equity Ratio | 1.36 | !28 | 5.54% |
| Debt Service Coverage Ratio | 0.14 | 0.17 | (t9.89%) |
| Return on Equity Ratio | 0.01 | 0.04 | (69.86%) |
| Inventory turnover ratio | 3.63 | 4.51 | (19.56%) |
| Trade Receivables turnover ratio | 3.05 | 3.84 | (20.66%) |
| Trade payables turnover ratio | 2.67 | 2.22 | 20.13% |
| Net capital turnover ratio | -9.29 | -8.44 | 10.03% |
| Net profit ratio | 0.44% | 1-1 • | (63.03F) |
| Return on Capital employed | 4.09% | 5.68% | (27.87%) |
| Return on investment | 0.00 | 0.00% | 0.00% |
Key Performance Indicators
(Amount in Lakhs, except EPS, % and ratios)
| Key Performance Indicator | For the six months ended September 30, 2023 | For the year ended March 31 , 2023 | For the year ended March 31, 2022 | For the year ended March 31, 2021 |
| Revenue from Operations | 1,132.00 | 2,214.71 | 2,097.52 | 2,504.71 |
| Total Income | 1,132.60 | 2,296.24 | 2,118.67 | 2,505.96 |
| EBITDA | 242.34 | 268.37 | 140.84 | 164.55 |
| EBITDA Margin (%) | 21.41% | 12.12% | 6.71% | 6.57% |
| Profit for the Year/Period | 129.11 | 95.78 | 9.23 | 29.81 |
| PAT Margin (%) | 11.41% | 4.32% | 0.44% | 1.19% |
| Return on Net Worth | 10.93% | 11.25% | 1.22% | 3.99% |
| Return on Capital Employed | 9.21% | 9.71% | 4.09% | 5.68% |
| Debt-Equity Ratio | 0.90 | 1.38 | 1.36 | 1.28 |
Profit & Loss
(₹ in lakhs)
| Particulars | For the period ended 30th September,2023 | For the year ended March 31 | ||
| 2023 | 2022 | 2021 | ||
| Revenue from Operations | 1,132.00 | 2,214.71 | 2,097.52 | 2,504.71 |
| Other Income | 0.60 | 81.53 | 21.15 | 1.25 |
| Total Income | 1,132.60 | 2,296.24 | 2,118.67 | 2,505.96 |
| EBITDA | 242.34 | 268.37 | 140.84 | 164.55 |
| EBITDA Margin (%) | 21.40% | 11.69% | 6.65% | 6.57% |
| Profit After Tax | 129.11 | 95.78 | 9.23 | 29.81 |
| PAT Margin (%) | 11.40% | 4.17% | 0.44% | 1.19% |
| ROE (%) | 12.70% | 11.92% | 1.23% | 4.08% |
| ROCE (%) | 9.21% | 9.71% | 4.09% | 5.68% |
Cash Flow
(₹ in lakhs)
| Particulars | Six-month period ended Sept 30, 2023 | March 31,2023 | March 31,2022 | March 31,2021 |
| Net Cash Flow from/ (used in) Operating Activities | (48.76) | (58.37) | 3.74 | (116.42) |
| Net cash generated from/ (used in) investing activities | (6.51) | (28.13) | (59.31) | (1.56) |
| Net Cash Flow from/ (used in) Financing Activities | 51.65 | 93.69 | 18.28 | 126.98 |
Capital structure
(In Lakhs)
| Particulars | Pre-Issue |
| Sept 30, 2023 | |
| Debt | |
| Short Term Debt | 1041.59 |
| Long Term Debt | 20.91 |
| Total Debt | 1062.50 |
| Shareholders’ Fund (Equity) | |
| Share Capital | 800.00 |
| Reserves & Surplus | 380.83 |
| Less: Miscellaneous Expenses not w/off | – |
| Total Shareholders’ Fund (Equity) | 1,180.83 |
| Long Term Debt/Equity | 0.02 |
| Total Debt/Equity | 0.90 |
SWOT
- Strength
- Good relations with established distributors
- Wide range of registered products
- Wide range of products under registration
- Weakness
- Dependency on buyers
- Lack of Brand Awareness
- Lack of firm arrangements of finance
- Opportunities
- Expanding new geographical markets
- Regulatory strength and documentation
- Wide range of products under registration
- Threats
- Fluctuation in raw material prices
- Competition from organised and unorganised players
- Change in government policies
IPO Details
Medicamen Organics IPO Details
| Detail | Information |
|---|---|
| Issue Type | SME IPO |
| Offer Size | Up to ₹10.54 Crore |
| Issue Price | ₹32 – ₹34 per share |
| Lot Size | 4,000 Shares |
| Minimum Investment | ₹136,000 (at upper price band) |
| Open Date | June 21, 2024 |
| Close Date | June 25, 2024 |
| Listing Exchange | NSE SME |
Ipo funds utilisation
(₹ in lakhs)
| Sr.No. | Particulars | Estimated amount |
| 1. | Funding of expenses proposed to be incurred towards Product registration in the international markets; | Up to 300.00 |
| 2. | Plant updation and increase in production capacity | Up to 225.00 |
| 3. | Funding working capital requirements of our Company | Up to 400.00 |
| 4. | General corporate purposes (1)(2) | [·] |
Litigation involved
Gray Market Premium
Latest posts
- Paramount Forge: A Risky Bet in a Volatile Market
- Pelatro IPO: Is the Aggressive Hype Over?
- Deccan Transcon Leasing IPO: Is This IPO a Alienated Dud?
- Osel Devices: A Blinded Cautionary Tale for IPO Investors
- Northern Arc Capital IPO: A Risky Bet?